Key Insights

Highlights

Treatment Research

13 treatments under study, led by Subprotocol F

Research Leaders

6 sponsors active, led by Biosensors Europe SA

Related Conditions

Often studied with 20 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

33.3%

2 terminated out of 6 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 2 (1)
Phase 2/3 (1)
Phase 3 (1)

Trial Status

Recruiting2
Terminated2
Unknown1
Enrolling By Invitation1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07444957Recruiting

Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease

NCT06657326Not ApplicableRecruiting

LEADERS FREE IV (RCT): BioFreedom™ Ultra vs BioFreedom™ in HBR Patients

NCT06763549Enrolling By Invitation

COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable

NCT02131142Phase 2/3Unknown

BioFreedom US IDE Feasibility Trial

NCT00944333Phase 3Terminated

Second Generation" Drug-Eluting Stents Implantation Followed by Six Versus Twelve-Month - Dual Antiplatelet Therapy

NCT00157001Phase 2Terminated

Feasibility Study of Photopheresis Post Angioplasty

Showing all 6 trials

Research Network

Common Treatments

  • Subprotocol F1
  • Subprotocol H1
  • Subprotocol C1
  • Subprotocol D1
  • Biofreedom Stainless Steel Biolimus A9coated Stent1

Active Sponsors

  • Biosensors Europe SA2
  • Fundación Interhospitalaria para la Investigación Cardiovascular FIC1
  • Therakos1
  • Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS1
  • Atlantic Health System1

Top Investigators

Related Conditions

  • Unstable Angina2
  • Heart Failure1
  • Lvf1
  • Cardiopulmonary Failure1
  • Cardiac Output Low1

Activity Timeline